With the rapid development of personalized medicine and genetic testing, individuals can now gain detailed insights into their potential health risks. While this information can improve prevention and treatment, its use by insurance companies to determine premiums or coverage raises serious ethical concerns. In my view, although limited use may be justifiable, strict safeguards must be implemented to protect individual privacy and prevent discrimination.
On the one hand, insurance companies argue that access to genetic information allows them to assess risk more accurately. From a business perspective, charging higher premiums to individuals with a greater likelihood of illness may seem fair, as insurance systems are traditionally based on risk calculation. Moreover, such data could encourage people to adopt healthier lifestyles if they are aware of their genetic vulnerabilities.
On the other hand, allowing insurers unrestricted access to genetic data is ethically problematic. Genetic information is highly personal and largely beyond an individual’s control. Penalizing people financially for inherited risks could lead to genetic discrimination, making insurance unaffordable for vulnerable groups. This would undermine the fundamental principle of insurance, which is to share risk across society rather than exclude those most in need of protection.
Therefore, strong safeguards are essential. First, governments should introduce clear legislation that prohibits insurers from using genetic data without explicit and informed consent. Second, genetic information should be strictly confidential and protected by robust data security systems to prevent misuse or unauthorized access. Finally, independent regulatory bodies should monitor insurance practices to ensure transparency and fairness.
In conclusion, while the use of genetic information by insurance companies may offer certain practical advantages, it is only ethically acceptable under strict regulation. Protecting individual privacy and preventing discrimination must remain the top priorities in the age of genetic medicine.